Zealand CEO about new purchase: "We have been extremely lucky"
Emmanuel Dulac, CEO of Zealand Pharma, is very satisfied that the company has obtained a drug candidate against inflammatory bowel diseases by so far paying nothing. The drug may compete for a share of a billion dollar market.
BY KEVIN GRØNNEMANN
The CEO of Zealand Pharma, Emmanuel Dulac, does not hesitate in his judgment on Tuesday's purchase of Canadian company Encycle Therapeutics, which Zealand only has to pay for if it is succesful.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
